| Year |
Citation |
Score |
| 2023 |
Cecchi F, Rex K, Schmidt J, Vocke CD, Lee YH, Burkett S, Baker D, Damore MA, Coxon A, Burgess TL, Bottaro DP. Rilotumumab Resistance Acquired by Intracrine Hepatocyte Growth Factor Signaling. Cancers. 15. PMID 36672409 DOI: 10.3390/cancers15020460 |
0.612 |
|
| 2022 |
Shah MA, Wainberg ZA, Catenacci DVT, Hochster HS, Ford J, Kunz P, Lee FC, Kallender H, Cecchi F, Rabe DC, Keer H, Martin AM, Liu Y, Gagnon R, Bonate P, et al. Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer. Plos One. 17: e0276211. PMID 36215283 DOI: 10.1371/journal.pone.0276211 |
0.499 |
|
| 2021 |
Shah MA, Wainberg ZA, Catenacci DVT, Hochster HS, Ford J, Kunz P, Lee FC, Kallender H, Cecchi F, Rabe DC, Keer H, Martin AM, Liu Y, Gagnon R, Bonate P, et al. Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer. Plos One. 16: e0261994. PMID 34941969 DOI: 10.1371/journal.pone.0261994 |
0.499 |
|
| 2021 |
Kummar S, Srivastava AK, Navas T, Cecchi F, Lee YH, Bottaro DP, Park SR, Do KT, Jeong W, Johnson BC, Voth AR, Rubinstein L, Wright JJ, Parchment RE, Doroshow JH, et al. Combination therapy with pazopanib and tivantinib modulates VEGF and c-MET levels in refractory advanced solid tumors. Investigational New Drugs. PMID 34180036 DOI: 10.1007/s10637-021-01138-x |
0.593 |
|
| 2020 |
Di Bartolomeo M, Raimondi A, Cecchi F, Catenacci DVT, Schwartz S, Sellappan S, Tian Y, Miceli R, Pellegrinelli A, Giommoni E, Aitini E, Spada F, Rosati G, Marchet A, Pucci F, et al. Association of high TUBB3 with resistance to adjuvant docetaxel-based chemotherapy in gastric cancer: translational study of ITACA-S. Tumori. 300891620930803. PMID 32522106 DOI: 10.1177/0300891620930803 |
0.318 |
|
| 2020 |
Solocinski K, Padget MR, Fabian KP, Wolfson B, Cecchi F, Hembrough T, Benz SC, Rabizadeh S, Soon-Shiong P, Schlom J, Hodge JW. Overcoming hypoxia-induced functional suppression of NK cells. Journal For Immunotherapy of Cancer. 8. PMID 32345623 DOI: 10.1136/Jitc-2019-000246 |
0.329 |
|
| 2019 |
Schaff LR, Yan D, Thyparambil S, Tian Y, Cecchi F, Rosenblum M, Reiner AS, Panageas KS, Hembrough T, Lin AL. Characterization of MGMT and EGFR protein expression in glioblastoma and association with survival. Journal of Neuro-Oncology. PMID 31823165 DOI: 10.1007/S11060-019-03358-X |
0.339 |
|
| 2019 |
Serna G, Ruiz-Pace F, Cecchi F, Fasani R, Jimenez J, Thyparambil S, Landolfi S, Elez E, Vivancos A, Hembrough T, Tabernero J, Dienstmann R, Nuciforo P. Targeted multiplex proteomics for molecular prescreening and biomarker discovery in metastatic colorectal cancer. Scientific Reports. 9: 13568. PMID 31537838 DOI: 10.1038/S41598-019-49867-7 |
0.408 |
|
| 2019 |
Toulmonde M, Pulido M, Ray-Coquard I, Andre T, Isambert N, Chevreau C, Penel N, Bompas E, Saada E, Bertucci F, Lebbe C, Le Cesne A, Soulie P, Piperno-Neumann S, Sweet S, ... Cecchi F, et al. Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study. The Lancet. Oncology. PMID 31331699 DOI: 10.1016/S1470-2045(19)30276-1 |
0.371 |
|
| 2019 |
Novoplansky O, Fury M, Prasad M, Yegodayev K, Zorea J, Cohen L, Pelossof R, Cohen L, Katabi N, Cecchi F, Joshua BZ, Popovtzer A, Baselga J, Scaltriti M, Elkabets M. MET activation confers resistance to cetuximab, and prevents HER2 and HER3 upregulation in head and neck cancer. International Journal of Cancer. PMID 30694565 DOI: 10.1002/Ijc.32170 |
0.391 |
|
| 2019 |
Schwartz S, Szeto C, Tian Y, Cecchi F, Corallo S, Calegari MA, Di Bartolomeo M, Morano F, Raimondi A, Fucà G, Martinetti A, De Pascalis I, Martini M, Belfiore A, Milione M, et al. Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase. European Journal of Cancer (Oxford, England : 1990). 107: 164-174. PMID 30579113 DOI: 10.1016/J.Ejca.2018.11.016 |
0.306 |
|
| 2019 |
Edenfield WJ, Merchant K, Martin JC, Drusbosky L, Elliott MH, Reddy SK, Szeto C, Cecchi F, Schammel C, Schammel DP, Grinstead RM, Chung KY. Selected reaction monitoring mass spectrometry (SRM-MS) evaluation of HER2 equivocal breast cancer. Journal of Clinical Oncology. 37. DOI: 10.1200/Jco.2019.37.15_Suppl.E12510 |
0.316 |
|
| 2019 |
Guo R, Offin M, Brannon AR, Chow A, Delasos L, Somwar R, Wilkins O, Scott K, Tian Y, Cecchi F, Hembrough TA, Li BT, Rudin CM, Kris MG, Arcila ME, et al. MET inhibitor resistance in patients with MET exon 14-altered lung cancers. Journal of Clinical Oncology. 37: 9006-9006. DOI: 10.1200/Jco.2019.37.15_Suppl.9006 |
0.387 |
|
| 2019 |
Pernas S, Villagrasa P, Nuciforo P, Vivancos A, Scaltriti M, Rodón J, Burgués O, Canes J, Dueñas M, Cecchi F, Vidal M, Lluch A, Perelló A, Llombart A, Dorca J, et al. Abstract P6-18-02: Primary and secondary results of the first nationwide molecular screening program in Spain for patients with advanced breast cancer (AGATA SOLTI-1301 study) Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-P6-18-02 |
0.378 |
|
| 2019 |
Toulmonde M, Lucchesi C, Verbeke S, Crombe A, Chaire V, Laroche A, Loarer FL, Bertucci F, Adam J, Bertolo F, Geneste D, Bianchini L, Dadone-Montaudie B, Hembrough T, Cecchi F, et al. Unravelling omics landscape and targeting oncogenic pathways in undifferentiated pleomorphic sarcomas (UPS) Annals of Oncology. 30. DOI: 10.1093/Annonc/Mdz283.012 |
0.323 |
|
| 2018 |
Lam J, Kim Y, Cecchi F, Woo S, Chambers A, Tan I, Ling CCW, Si-Lin K, Qiang LW, Hon TLK, Jacobsen SAM, Hembrough T. The prognostic role of microsatellite status, tumor mutational burden and protein expression in CRC. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: v103. PMID 32176988 DOI: 10.1093/Annonc/Mdy149.007 |
0.302 |
|
| 2018 |
Sanchez-Vega F, Hechtman JF, Castel P, Ku GY, Tuvy Y, Won H, Fong CJ, Bouvier N, Nanjangud GJ, Soong J, Vakiani E, Schattner M, Kelsen DP, Lefkowitz RA, Brown K, ... ... Cecchi F, et al. EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer. Cancer Discovery. PMID 30463996 DOI: 10.1158/2159-8290.Cd-18-0598 |
0.421 |
|
| 2018 |
Li BT, Shen R, Buonocore D, Olah ZT, Ni A, Ginsberg MS, Ulaner GA, Offin M, Feldman D, Hembrough T, Cecchi F, Schwartz S, Pavlakis N, Clarke S, Won HH, et al. Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2018779777. PMID 29989854 DOI: 10.1200/Jco.2018.77.9777 |
0.405 |
|
| 2018 |
Wong GS, Zhou J, Liu JB, Wu Z, Xu X, Li T, Xu D, Schumacher SE, Puschhof J, McFarland J, Zou C, Dulak A, Henderson L, Xu P, O'Day E, ... ... Cecchi F, et al. Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. Nature Medicine. PMID 29808010 DOI: 10.1038/S41591-018-0022-X |
0.421 |
|
| 2018 |
Mahjoubi L, Cecchi F, Massard C, Calabro F, Gazzah A, Bahleda R, Jamme P, Gelli M, Goere D, Lacroix L, Adam J, Heukamp L, Trenta P, Hembrough T, Soria JC, et al. Personalized therapy based on sequential molecular analysis leads to 30 months of survival in a patient with diffuse unresectable gastric linitis plastica. Tumori. 104: NP38-NP41. PMID 29714649 DOI: 10.1177/0300891618763215 |
0.326 |
|
| 2018 |
Kim YJ, Chambers AG, Cecchi F, Hembrough T. Targeted data-independent acquisition for mass spectrometric detection of RAS mutations in formalin-fixed, paraffin-embedded tumor biopsies. Journal of Proteomics. PMID 29684684 DOI: 10.1016/J.Jprot.2018.04.022 |
0.303 |
|
| 2018 |
Maron SB, Alpert L, Kwak HA, Lomnicki S, Chase L, Xu D, O'Day E, Nagy RJ, Lanman RB, Cecchi F, Hembrough T, Schrock A, Hart J, Xiao SY, Setia N, et al. Targeted therapies for targeted populations: Anti-EGFR treatment for EGFR amplified gastroesophageal adenocarcinoma. Cancer Discovery. PMID 29449271 DOI: 10.1158/2159-8290.Cd-17-1260 |
0.345 |
|
| 2018 |
Yan D, Hong JH, Lee HY, Byun JH, Cecchi F, Tian Y, Schwartz S, An E, Hembrough TA. Selecting patients with stage II/III colorectal cancer for 5-fluorouracil-based adjuvant chemotherapy using proteomic analysis. Journal of Clinical Oncology. 36: 708-708. DOI: 10.1200/Jco.2018.36.4_Suppl.708 |
0.348 |
|
| 2018 |
Schwartz S, Tian Y, Cecchi F, Nguyen A, Kim YJ, Goh B, Chew MH, Tang CL, Toh E, Skanderup A, Koo S, Chua CWL, Leow WQ, Tan IB, Vaske CJ, et al. The prognostic role of microsatellite status, tumor mutational burden, and protein expression in CRC. Journal of Clinical Oncology. 36: 572-572. DOI: 10.1200/Jco.2018.36.4_Suppl.572 |
0.322 |
|
| 2018 |
Gasparini E, Cecchi F, di Cicilia R, Kuhn E, Falco G, Ferrari G, Foroni M, Tamagnini I, Bassano C, Tian Y, Benz SC, Hembrough TA, Bisagni A. Predicting pathological complete response (pCR) to neoadjuvant trastuzumab in patients with breast cancer using HER2 mass spectrometry. Journal of Clinical Oncology. 36: e12643-e12643. DOI: 10.1200/Jco.2018.36.15_Suppl.E12643 |
0.366 |
|
| 2018 |
An E, Hong S, An HJ, Thyparambil SP, SELLAPPAN S, Yan D, Tian Y, Cecchi F, Hembrough TA, Kim TJ. Identifying treatment options for SCLC patients with multiplexed clinical proteomic testing. Journal of Clinical Oncology. 36: 8574-8574. DOI: 10.1200/Jco.2018.36.15_Suppl.8574 |
0.333 |
|
| 2018 |
Thyparambil SP, Kim YJ, Chambers A, Yan D, SELLAPPAN S, Gong C, Sedgewick A, Newton Y, Sanborn JZ, Vaske CJ, Benz SC, Cecchi F, Kang H, Hembrough TA. Comprehensive proteomic and genomic profiling to identify therapeutic targets in adenoid cystic carcinoma. Journal of Clinical Oncology. 36: 6053-6053. DOI: 10.1200/Jco.2018.36.15_Suppl.6053 |
0.34 |
|
| 2018 |
Schwartz S, Cecchi F, Tian Y, Yau C, Szeto C, Rübner M, Erber R, Beckmann M, Hartmann A, Benz S, Hembrough T, Fasching P. Abstract P2-10-06: Identifying patients sensitive to anthracycline-containing therapy with quantitative proteomic and genomic profiling Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P2-10-06 |
0.382 |
|
| 2018 |
Thyparambil SP, Kim YJ, Chambers AG, Yan D, Sellappan S, Sedgewick AJ, Newton Y, Sanborn JZ, Vaske CJ, Benz SC, Cecchi F, Kang H, Hembrough TA. Abstract 778: Potential drug targets for adenoid cystic carcinoma elucidated by proteogenomic analysis Cancer Research. 78: 778-778. DOI: 10.1158/1538-7445.Am2018-778 |
0.399 |
|
| 2018 |
Schwartz S, Heaton R, Tian Y, Sanborn Z, Sellappan S, Cecchi F, Benz S, Hembrough T. Abstract B200: Using “omics” to select immunotherapy and conventional therapy combinations Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-B200 |
0.385 |
|
| 2018 |
Yan D, Schaff L, Cecchi F, Benz S, Rosenblum M, Hembrough T, Lin A. COMP-16. CORRELATING MGMT PROTEIN LEVEL WITH TEMOZOLOMIDE RESPONSE IN GLIOBLASTOMA PATIENTS USING MASS SPECTROMETRY Neuro-Oncology. 20: vi67-vi67. DOI: 10.1093/Neuonc/Noy148.271 |
0.319 |
|
| 2018 |
Fasani R, Comerma L, Pagliuca F, Thyparambil S, Peg V, Jimenez J, Cecchi F, Hembrough T, Perez J, Arribas J, Cortes J, Scaltriti M, Saura C, Nuciforo P. Tumor-infiltrating lymphocytes density correlates with HER2 gene copy number but not with protein levels in HER2-positive breast cancer European Journal of Cancer. 92. DOI: 10.1016/S0959-8049(18)30608-7 |
0.326 |
|
| 2018 |
Li B, Offin M, Hembrough T, Cecchi F, Shen R, Olah Z, Panora E, Myers M, Brzostowski E, Buonocore D, Ginsberg M, Rudin C, Kris M, Weitsman G, Barber P, et al. P1.13-43 Molecular and Imaging Predictors of Response to Ado-Trastuzumab Emtansine in Patients with HER2 Mutant Lung Cancers: An Exploratory Phase 2 Trial Journal of Thoracic Oncology. 13: S599. DOI: 10.1016/J.Jtho.2018.08.900 |
0.31 |
|
| 2017 |
Schwartz S, Cecchi F, Tian Y, Scott K, Di Bartolomeo M, Morano F, Fucà G, Martinetti A, de Braud F, Dominoni F, Milione M, Calegari Maria A, Orlandi A, Barone C, Pietrantonio F, et al. Selecting patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of MGMT. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 28: iii95. PMID 32136077 DOI: 10.1093/Annonc/Mdx261.270 |
0.345 |
|
| 2017 |
Cecchi F, Catenacci D, Schwartz S, Tian Y, Miceli R, Pietrantonio F, Martinetti A, Di Bartolomeo M, Hembrough T, Pellegrinelli A. Predicting survival in gastric cancer patients randomized to docetaxel with mass spectrometric quantitation of TUBB3. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 28: iii3-iii4. PMID 32135857 DOI: 10.1093/Annonc/Mdx263.006 |
0.318 |
|
| 2017 |
Yao Z, Yaeger R, Rodrik-Outmezguine VS, Tao A, Torres NM, Chang MT, Drosten M, Zhao H, Cecchi F, Hembrough T, Michels J, Baumert H, Miles L, Campbell NM, de Stanchina E, et al. Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS. Nature. PMID 28783719 DOI: 10.1038/Nature23291 |
0.308 |
|
| 2017 |
De Silva DM, Roy A, Kato T, Cecchi F, Lee YH, Matsumoto K, Bottaro DP. Targeting the hepatocyte growth factor/Met pathway in cancer. Biochemical Society Transactions. PMID 28673936 DOI: 10.1042/Bst20160132 |
0.8 |
|
| 2017 |
Toki MI, Cecchi F, Hembrough T, Syrigos KN, Rimm DL. Proof of the quantitative potential of immunofluorescence by mass spectrometry. Laboratory Investigation; a Journal of Technical Methods and Pathology. PMID 28092364 DOI: 10.1038/Labinvest.2016.148 |
0.334 |
|
| 2017 |
Cecchi F, Catenacci DVT, Tian Y, Miceli R, Pietrantonio F, Pellegrinelli A, Martinetti A, Bartolomeo MD, Hembrough TA. Quantitative proteomic analysis of TUBB3 to identify gastric cancer patients who may benefit from docetaxel: A reevaluation of the ITACA-S trial. Journal of Clinical Oncology. 35: 59-59. DOI: 10.1200/Jco.2017.35.4_Suppl.59 |
0.362 |
|
| 2017 |
Cecchi F, Catenacci DVT, Schwartz S, Sellappan S, Tian Y, Miceli R, Pietrantonio F, Pellegrinelli A, Martinetti A, Bartolomeo MD, Hembrough TA. Predicting survival in gastric cancer patients randomized to docetaxel with mass spectrometric quantitation of TUBB3. Journal of Clinical Oncology. 35: 4068-4068. DOI: 10.1200/Jco.2017.35.15_Suppl.4068 |
0.325 |
|
| 2017 |
Schwartz S, Cecchi F, Tian Y, Scott K, Bartolomeo MD, Morano F, Fucà G, Martinetti A, Braud FGD, Dominoni F, Milione M, Calegari MA, Orlandi A, Barone C, Pietrantonio F, et al. Selecting patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of MGMT. Journal of Clinical Oncology. 35: 11601-11601. DOI: 10.1200/Jco.2017.35.15_Suppl.11601 |
0.368 |
|
| 2017 |
Schwartz S, Tian Y, Fasani R, Delgado MD, Hierro C, Rodon J, Sellappan S, Cecchi F, Hembrough T, Nuciforo P. Abstract P6-07-16: Quantitative proteomic analysis of FGFR by mass spectrometry may improve identification of FGFR amplified tumors sensitive to inhibitor therapy Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P6-07-16 |
0.42 |
|
| 2017 |
Sellappan S, Schwartz S, Wertheimer E, Cecchi F, Mamus SW, Catenacci DV, Hembrough T. Abstract 735: HER2 protein quantification in multiple cancer indications identifies candidates for HER2 targeted therapies Cancer Research. 77: 735-735. DOI: 10.1158/1538-7445.Am2017-735 |
0.422 |
|
| 2017 |
Yao Z, Yaeger R, Rodrik-Outmezguine VS, Tao A, Torres NM, Chang MT, Drosten M, Zhao H, Cecchi F, Hembrough T, Michels J, Baumert H, Miles L, Campbell NM, Stanchina Ed, et al. Abstract 4078: Tumors with class 3 BRAF mutants are sensitive to the inhibition of activated RAS Cancer Research. 77: 4078-4078. DOI: 10.1158/1538-7445.Am2017-4078 |
0.321 |
|
| 2017 |
Cecchi F, Catenacci D, Schwartz S, Sellappan S, Tian Y, Miceli R, Pietrantonio F, Pellegrinelli A, Martinetti A, Bartolomeo MD, Hembrough T. 146PPredicting response to chemotherapy in gastric cancer patients randomized to docetaxel: A reevaluation of the ITACA-S trial Annals of Oncology. 28. DOI: 10.1093/Annonc/Mdx363.062 |
0.301 |
|
| 2017 |
Velcheti V, Schwartz S, Cecchi F, Tian Y, Sellappan S, Rudin C, Poirier J, Hembrough T. P1.02-001 SLFN11 Expression in Early Stage Non-Small Cell Lung Cancer Predicts Benefit from Adjuvant Chemotherapy with Taxane and Platinum Journal of Thoracic Oncology. 12: S1924-S1925. DOI: 10.1016/J.Jtho.2017.09.733 |
0.317 |
|
| 2016 |
Toki M, Cecchi F, Hembrough T, Syrigos K, Rimm D. PS01.30: Domain-Specific c-Met Measurement by Quantitative Immunofluorescence and Mass Spectrometry in Non-Small Cell Lung Cancer: Topic: Pathology. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 11: S287. PMID 27969497 DOI: 10.1016/J.Jtho.2016.09.065 |
0.321 |
|
| 2016 |
Catenacci DV, Ang A, Liao WL, Shen J, O'Day E, Loberg RD, Cecchi F, Hembrough T, Ruzzo A, Graziano F. MET tyrosine kinase receptor expression and amplification as prognostic biomarkers of survival in gastroesophageal adenocarcinoma. Cancer. PMID 27926778 DOI: 10.1002/Cncr.30437 |
0.356 |
|
| 2016 |
An E, Ock CY, Kim TY, Lee KH, Han SW, Im SA, Kim TY, Liao WL, Cecchi F, Blackler A, Thyparambil S, Kim WH, Burrows J, Hembrough T, Catenacci D, et al. Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 27687309 DOI: 10.1093/Annonc/Mdw442 |
0.353 |
|
| 2016 |
Kaye DR, Pinto PA, Cecchi F, Reilly J, Semerjian A, Rabe DC, Gupta G, Choyke PL, Bottaro DP. Tumor and Plasma Met Levels in Non-Metastatic Prostate Cancer. Plos One. 11: e0157130. PMID 27300295 DOI: 10.1371/Journal.Pone.0157130 |
0.759 |
|
| 2016 |
Sellappan S, Blackler A, Liao WL, O'Day E, Xu P, Thyparambil S, Cecchi F, Hembrough T, Catenacci DV. Therapeutically Induced Changes in HER2, HER3, and EGFR Protein Expression for Treatment Guidance. Journal of the National Comprehensive Cancer Network : Jnccn. 14: 503-7. PMID 27160229 DOI: 10.6004/Jnccn.2016.0059 |
0.369 |
|
| 2016 |
Henderson L, Xu P, O'Day E, Cecchi F, Blackler A, Liao W, Hembrough TA, Catenacci DVT. KRAS gene amplification to define a distinct molecular subgroup of gastroesophageal adenocarcinoma. Journal of Clinical Oncology. 34: 4065-4065. DOI: 10.1200/Jco.2016.34.4_Suppl.74 |
0.333 |
|
| 2016 |
Soon-Shiong P, Rabizadeh S, Benz S, Cecchi F, Hembrough T, Mahen E, Burton K, Song C, Senecal F, Schmechel S, Pritchard C, Dorschner M, Blau S, Blau A. Abstract P6-05-08: Integrating whole exome sequencing data with RNAseq and quantitative proteomics to better inform clinical treatment decisions in patients with metastatic triple negative breast cancer Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P6-05-08 |
0.355 |
|
| 2016 |
Benz S, Rabizadeh S, Cecchi F, Beckman M, Brucker S, Hartmann A, Golovato J, Hembrough T, Janni W, Rack B, Sanborn J, Schneeweiss A, Vaske C, Soon-Shiong P, Fasching P. Abstract P6-04-14: Integrating whole genome sequencing data with RNAseq, pathway analysis, and quantitative proteomics to determine prognosis after standard adjuvant treatment with trastuzumab and chemotherapy in primary breast cancer patients Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P6-04-14 |
0.345 |
|
| 2016 |
Nuciforo P, Thyparambil S, Galván P, Vilaro M, Jimenez J, Liao W, Cecchi F, Blackler A, Press M, Gagnon R, Ellis C, Hembrough T, Johnston S, Prat A. Abstract P3-07-08: Quantitative HER family proteins assessment as prognostic and predictive biomarkers in the EGF30008 clinical trial Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P3-07-08 |
0.406 |
|
| 2016 |
Cecchi F, Ku N, Wang H, Blackler A, Hembrough T, Rabizadeh S, Soon-Shiong P, Huang J. Abstract 4935: Targeted proteomic analysis of hepatocellular carcinoma and its histologic mimickers Cancer Research. 76: 4935-4935. DOI: 10.1158/1538-7445.Am2016-4935 |
0.353 |
|
| 2016 |
Cecchi F, Thyparambil S, Blackler A, Hembrough T, Rabizadeh S, Soon-Shiong P, Frierson H, Theodorescu D. Abstract 449: Targeted proteomic analysis for personalized treatment of muscle invasive bladder cancer Cancer Research. 76: 449-449. DOI: 10.1158/1538-7445.Am2016-449 |
0.421 |
|
| 2016 |
Cecchi F, Schwartz S, Sellappan S, Thyparambil S, Hembrough T. Targeted proteomic analysis of bone metastases from lung cancer and other malignancies European Journal of Cancer. 69. DOI: 10.1016/S0959-8049(16)32954-9 |
0.312 |
|
| 2015 |
Catenacci DV, Liao WL, Zhao L, Whitcomb E, Henderson L, O'Day E, Xu P, Thyparambil S, Krizman D, Bengali K, Uzzell J, Darfler M, Cecchi F, Blackler A, Bang YJ, et al. Mass-spectrometry-based quantitation of Her2 in gastroesophageal tumor tissue: comparison to IHC and FISH. Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. PMID 26581548 DOI: 10.1007/S10120-015-0566-0 |
0.335 |
|
| 2015 |
Jagoda EM, Bhattacharyya S, Kalen J, Riffle L, Leeder A, Histed S, Williams M, Wong KJ, Xu B, Szajek LP, Elbuluk O, Cecchi F, Raffensperger K, Golla M, Bottaro DP, et al. Imaging the Met Receptor Tyrosine Kinase (Met) and Assessing Tumor Responses to a Met Tyrosine Kinase Inhibitor in Human Xenograft Mouse Models with a [99mTc] (AH-113018) or Cy 5** (AH-112543) Labeled Peptide. Molecular Imaging. 14: 499-515. PMID 26461980 DOI: 10.2310/7290.2015.00023 |
0.595 |
|
| 2015 |
Nuciforo P, Thyparambil S, Aura C, Garrido-Castro A, Vilaro M, Peg V, Jimenez J, Vicario R, Cecchi F, Hoos W, Burrows J, Hembrough T, Ferreres JC, Perez-Garcia J, Arribas J, et al. High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy. Molecular Oncology. PMID 26422389 DOI: 10.1016/J.Molonc.2015.09.002 |
0.365 |
|
| 2015 |
Shapiro GI, McCallum S, Adams LM, Sherman L, Weller S, Swann S, Keer H, Miles D, Müller T, Rabe DC, Cecchi F, Bottaro DP, LoRusso P. Erratum to: A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors. Investigational New Drugs. PMID 26407571 DOI: 10.1007/S10637-015-0287-6 |
0.565 |
|
| 2015 |
Cecchi F, Lih CJ, Lee YH, Walsh W, Rabe DC, Williams PM, Bottaro DP. Expression array analysis of the hepatocyte growth factor invasive program. Clinical & Experimental Metastasis. 32: 659-76. PMID 26231668 DOI: 10.1007/S10585-015-9735-0 |
0.682 |
|
| 2015 |
Ock C, An E, Oh D, Kim T, Lee K, Han S, Im S, Kim T, Liao W, Cecchi F, Blackler A, Thyparambil SP, Hoos WA, Kim WH, Burrows J, et al. Quantitative measurement of HER2 levels by multiplexed mass spectrometry to predict survival in gastric cancer patients treated with trastuzumab. Journal of Clinical Oncology. 33: 4050-4050. DOI: 10.1200/Jco.2015.33.15_Suppl.4050 |
0.362 |
|
| 2015 |
Hembrough TA, Cecchi F, Blackler A, Thyparambil SP, Burrows J, O'Shaughnessy J. Proteomic analysis of primary and metastatic breast cancers and expression of the folate receptor as a potential drug target. Journal of Clinical Oncology. 33: 1045-1045. DOI: 10.1200/Jco.2015.33.15_Suppl.1045 |
0.41 |
|
| 2015 |
Blackler A, Liao W, Thyparambil S, An E, Cecchi F, Darfler M, Hembrough T, Burrows J. Abstract 3398: Development of a mass spectrometry based antibody-drug conjugate biomarker panel Cancer Research. 75: 3398-3398. DOI: 10.1158/1538-7445.Am2015-3398 |
0.376 |
|
| 2015 |
Cecchi F, Liao W, Thyparambil S, Darfler M, Krizman D, Hembrough T, Burrows J, Bottaro D, Catenacci DVT. Abstract 3397: A novel clinical tool that provides quantitative and accurate measurement of Met protein Cancer Research. 75: 3397-3397. DOI: 10.1158/1538-7445.Am2015-3397 |
0.404 |
|
| 2015 |
Cecchi F, Blackler A, Jordan H, Darfler M, Hembrough T, Stocum M, Burrows J. Abstract 3395: Clinical Survey of 19 actionable proteins in multiple indications using multiplex mass spectrometry Cancer Research. 75: 3395-3395. DOI: 10.1158/1538-7445.Am2015-3395 |
0.406 |
|
| 2015 |
Cecchi F, Blackler A, Jordan H, Stocum M, Darfler M, Hembrough T, Burrow J. Clinical Survey of actionable proteins in multiple indications using multiplex mass spectrometry Annals of Oncology. 26: ii21. DOI: 10.1093/Annonc/Mdv092.2 |
0.379 |
|
| 2015 |
Catenacci D, Shen J, Liao W, Oliner K, Ang A, Loberg R, O'Day E, Xu P, Henderson L, Cecchi F, Burrows J, Hembrough T, Ruzzo A, Graziano F. 2397 Evaluation of MET using FISH, IHC, or mass spectrometry as a prognostic biomarker in patients with gastroesophageal cancer European Journal of Cancer. 51: S469. DOI: 10.1016/S0959-8049(16)31313-2 |
0.341 |
|
| 2015 |
Kaye DR, Pinto PA, Cecchi F, Reilly J, Semerjian A, Giubellino A, Gupta G, Choyke PL, Linehan WM, Bottaro DP. MP6-17 PREDICTIVE VALUE OF PLASMA SOLUBLE MET PROTEIN CONCENTRATION IN PATIENTS WITH PROSTATE CANCER Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.264 |
0.744 |
|
| 2014 |
McNeil BK, Sorbellini M, Grubb RL, Apolo A, Cecchi F, Athauda G, Cohen B, Giubellino A, Simpson H, Agarwal PK, Coleman J, Getzenberg RH, Netto GJ, Shih J, Linehan WM, et al. Preliminary evaluation of urinary soluble Met as a biomarker for urothelial carcinoma of the bladder. Journal of Translational Medicine. 12: 199. PMID 25335552 DOI: 10.1186/1479-5876-12-199 |
0.787 |
|
| 2014 |
Catenacci DV, Liao WL, Thyparambil S, Henderson L, Xu P, Zhao L, Rambo B, Hart J, Xiao SY, Bengali K, Uzzell J, Darfler M, Krizman DB, Cecchi F, Bottaro DP, et al. Absolute quantitation of Met using mass spectrometry for clinical application: assay precision, stability, and correlation with MET gene amplification in FFPE tumor tissue. Plos One. 9: e100586. PMID 24983965 DOI: 10.1371/Journal.Pone.0100586 |
0.593 |
|
| 2014 |
Hembrough TA, Liao W, Thyparambil S, Henderson L, Rambo B, Cecchi F, Bottaro DP, Darfler M, Xu P, Xiao S, Zhao L, Veenstra TD, Burrows J, Catenacci DVT. Quantification of MET expression using mass spectrometry (MS): Assay precision and stability in FFPE tumor tissue. Journal of Clinical Oncology. 32: 16-16. DOI: 10.1200/Jco.2014.32.3_Suppl.16 |
0.548 |
|
| 2014 |
Cecchi F, Lih J, Lee Y, Walsh W, Williams M, Bottaro DP. Abstract 5259: Gene expression array and pathway profiling analyses distinguish HGF/Met pathways driving cell proliferation from invasion and identify events correlated with prostate cancer progression Cancer Research. 74: 5259-5259. DOI: 10.1158/1538-7445.Am2014-5259 |
0.679 |
|
| 2014 |
Cecchi F, Liao W, Thyparambil S, Bengali K, Uzzell J, Darflar M, Krizman D, Burrows J, Hembrough T, Veenstra T, Bottaro D, Karrison T, Henderson L, Xu P, Rambo B, et al. 537 Absolute quantitation of MET using mass spectrometry for clinical application: assay precision, stability, and correlation with MET gene amplification in FFPE tumor tissue European Journal of Cancer. 50: 175. DOI: 10.1016/S0959-8049(14)70663-X |
0.54 |
|
| 2013 |
Lee YH, Cecchi F, Agarwal PK, Parnes HL, Khadar K, Summerell A, Gulley JL, Compton K, Figg WD, Dahut WL, Bottaro DP. Preclinical and correlative studies of cabozantinib (XL184) in urothelial cancer (UC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 314. PMID 28136967 DOI: 10.1200/Jco.2013.31.15_Suppl.4543 |
0.677 |
|
| 2013 |
Shah MA, Wainberg ZA, Catenacci DV, Hochster HS, Ford J, Kunz P, Lee FC, Kallender H, Cecchi F, Rabe DC, Keer H, Martin AM, Liu Y, Gagnon R, Bonate P, et al. Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer. Plos One. 8: e54014. PMID 23516391 DOI: 10.1371/Journal.Pone.0054014 |
0.59 |
|
| 2013 |
Shah MA, Wainberg ZA, Catenacci DVT, Hochster HS, Ford J, Kunz P, Lee F, Kallender H, Cecchi F, Rabe DC, Keer H, Martin A, Liu Y, Gagnon R, Bonate P, et al. Patient enrollment and participation flow chart. Plos One. DOI: 10.1371/Journal.Pone.0054014.G001 |
0.485 |
|
| 2013 |
Wright CE, Jagoda E, Cecchi F, Bhadrasetty V, Histed S, Williams M, Kramer-Marek G, Mena E, Rosenblum L, Lang L, Szajek L, Paik C, Choyke PL, Marik J, Tinianow J, et al. Developing a molecular imaging agent for Met using onartuzumab (MetMAb). Journal of Clinical Oncology. 31: 11083-11083. DOI: 10.1200/Jco.2013.31.15_Suppl.11083 |
0.605 |
|
| 2013 |
Cecchi F, Rex K, Schmidt J, Baker D, Damore MA, Coxon A, Burgess TL, Bottaro DP. Abstract 5637: A cellular model of acquired resistance to rilotumumab (AMG 102) in glioblastoma. Cancer Research. 73: 5637-5637. DOI: 10.1158/1538-7445.Am2013-5637 |
0.641 |
|
| 2013 |
Cecchi F, Lih C, Lee YH, Walsh WD, Williams MP, Bottaro DP. Abstract 4085: Experimental metastasis by the prostate adenocarcinoma-derived cell line PC3M is driven by partial activation of the human Met pathway. Cancer Research. 73: 4085-4085. DOI: 10.1158/1538-7445.Am2013-4085 |
0.669 |
|
| 2012 |
Cecchi F, Bottaro DP. Novel antagonists of heparin binding growth factors. Oncotarget. 3: 911-2. PMID 22989865 DOI: 10.18632/Oncotarget.645 |
0.558 |
|
| 2012 |
Jagoda EM, Lang L, Bhadrasetty V, Histed S, Williams M, Kramer-Marek G, Mena E, Rosenblum L, Marik J, Tinianow JN, Merchant M, Szajek L, Paik C, Cecchi F, Raffensperger K, et al. Immuno-PET of the hepatocyte growth factor receptor Met using the 1-armed antibody onartuzumab. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 53: 1592-600. PMID 22917884 DOI: 10.2967/Jnumed.111.102293 |
0.611 |
|
| 2012 |
Cecchi F, Pajalunga D, Fowler CA, Uren A, Rabe DC, Peruzzi B, Macdonald NJ, Blackman DK, Stahl SJ, Byrd RA, Bottaro DP. Targeted disruption of heparan sulfate interaction with hepatocyte and vascular endothelial growth factors blocks normal and oncogenic signaling. Cancer Cell. 22: 250-62. PMID 22897854 DOI: 10.1016/J.Ccr.2012.06.029 |
0.779 |
|
| 2012 |
Cecchi F, Rabe DC, Bottaro DP. Targeting the HGF/Met signaling pathway in cancer therapy. Expert Opinion On Therapeutic Targets. 16: 553-72. PMID 22530990 DOI: 10.1517/14728222.2012.680957 |
0.653 |
|
| 2012 |
Kauffman E, Gupta G, Cecchi F, Raffensperger K, Linehan WM, Bottaro DP, Srinivasan R. 448 CHARACTERIZATION OF THE AKT-MTOR PATHWAY IN TFE3-FUSION RENAL CELL CANCERS AND IMPLICATIONS FOR TARGETED THERAPY Journal of Urology. 187. DOI: 10.1016/J.Juro.2012.02.515 |
0.583 |
|
| 2011 |
Merchant M, Marik J, Peng J, Williams SP, Ogasawara A, Tinianow JN, Bhadrasetty V, Lang L, Lee SM, Kim I, Williams M, Szajek L, Raffensperger KE, Cecchi F, Jagoda E, et al. Proof of concept of immuno-PET molecular imaging of met using (76)Br- and (89)Zr-labeled MetMAb. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 10632. PMID 28022451 DOI: 10.1200/Jco.2011.29.15_Suppl.10632 |
0.638 |
|
| 2011 |
Cecchi F, Pajalunga D, Fowler A, Rabe DC, Peruzzi B, MacDonald NJ, Blackman DK, Stahl SJ, Byrd A, Bottaro DP. A hepatocyte growth factor antagonist engineered by site-directed mutagenesis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 10528. PMID 28021761 DOI: 10.1200/Jco.2011.29.15_Suppl.10528 |
0.761 |
|
| 2011 |
Cecchi F, Rabe DC, Bottaro DP. The Hepatocyte Growth Factor Receptor: Structure, Function and Pharmacological Targeting in Cancer. Current Signal Transduction Therapy. 6: 146-151. PMID 25197268 DOI: 10.2174/157436211795659955 |
0.672 |
|
| 2011 |
Cecchi F, Rex K, Schmidt J, Baker D, Damore MA, Coxon A, Burgess TL, Bottaro DP. Abstract A204: A cellular model of acquired resistance to rilotumumab (AMG 102) in glioblastoma. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-A204 |
0.65 |
|
| 2010 |
Mungunsukh O, Lee YH, Marquez AP, Cecchi F, Bottaro DP, Day RM. A tandem repeat of a fragment of Listeria monocytogenes internalin B protein induces cell survival and proliferation. American Journal of Physiology. Lung Cellular and Molecular Physiology. 299: L905-14. PMID 20889677 DOI: 10.1152/Ajplung.00094.2010 |
0.733 |
|
| 2010 |
Cecchi F, Rabe DC, Bottaro DP. Targeting the HGF/Met signalling pathway in cancer. European Journal of Cancer (Oxford, England : 1990). 46: 1260-70. PMID 20303741 DOI: 10.1016/J.Ejca.2010.02.028 |
0.659 |
|
| 2010 |
Cecchi F, Pajalunga D, McNeil B, Rabe D, Fowler A, Liu Y, Gagnon CR, Kallender H, Shah MA, Getzenberg R, Schoenberg M, Martin A, Srinivasan R, Linehan WM, Byrd RA, et al. Abstract SY23-03: Oncogenic signal transduction via the hepatocyte growth factor/Met receptor kinase pathway Cellular and Molecular Biology. DOI: 10.1158/1538-7445.Am10-Sy23-03 |
0.779 |
|
| 2010 |
Cecchi F, Pajalunga D, Rabe DC, Peruzzi B, Fowler AC, Blackman DK, MacDonald N, Stahl SJ, Byrd AR, Bottaro DP. Abstract 342: A hepatocyte growth factor antagonist engineered by disruption of heparan sulfate binding Cancer Research. 70: 342-342. DOI: 10.1158/1538-7445.Am10-342 |
0.78 |
|
| 2010 |
Niswander LM, Guenther LM, Cecchi F, Giubellino A, Bottaro DP, Christensen JG, Khanna C, Helman LJ, Kim SY. Abstract 3401: Genetic down-regulation of MET alters the metastatic phenotype of osteosarcoma cells Cancer Research. 70: 3401-3401. DOI: 10.1158/1538-7445.Am10-3401 |
0.746 |
|
| 2009 |
Cecchi F, Pajalunga D, Rabe D, Fowler AC, MacDonald N, Blackman DK, Stahl SJ, Byrd AR, Bottaro DP. Abstract B228: A hepatocyte growth factor antagonist engineered by targeted disruption of heparan sulfate binding Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-B228 |
0.795 |
|
| 2009 |
Cecchi F, Liu Y, Gagnon RC, Kallender H, Rabe DC, Shah MA, Martin A, Bottaro DP. Abstract B210: Shed MET (sMET), VEGFA, and sVEGFR2 are markers of foretinib treatment in metastatic gastric cancer patients Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-B210 |
0.572 |
|
| 2009 |
LoRusso P, Eder JP, Sherman L, McCallum S, Liu Y, Bottaro D, Cecchi F, Rabe D, Miles D, Shapiro G. Abstract A8: Final results of a phase I dose escalation study of the safety and pharmacokinetics of foretinib administered orally daily to patients with solid tumors Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-A8 |
0.55 |
|
| 2004 |
Pacini S, Ruggiero M, Cecchi F, Peruzzi B, Vannucchi S. Proteolysis of human plasma reveals the presence of complexes formed by endogenous heparin and peptides that stimulate angiogenesis. Oncology Research. 14: 501-11. PMID 15559764 DOI: 10.3727/0965040042380469 |
0.658 |
|
| Show low-probability matches. |